Sagimet Biosciences (SGMT) Set to Post Quarterly Earnings on Thursday

Sagimet Biosciences (NASDAQ:SGMT) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.17 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Sagimet Biosciences (NASDAQ:SGMT) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). On average, analysts expect Sagimet Biosciences to post ($1.14) EPS for the current fiscal year and ($1.06) EPS for the next fiscal year.

Sagimet Biosciences Stock Up 0.6%

Shares of SGMT stock opened at $10.89 on Wednesday. The stock’s 50-day moving average price is $9.88 and its 200 day moving average price is $7.61. The stock has a market capitalization of $676.92 million, a PE ratio of -8.51 and a beta of 3.43. Sagimet Biosciences has a 52-week low of $4.50 and a 52-week high of $11.45.

Wall Street Analysts Forecast Growth

SGMT has been the topic of several analyst reports. Guggenheim lifted their target price on Sagimet Biosciences from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, October 2nd. Citigroup restated a “market outperform” rating on shares of Sagimet Biosciences in a research note on Thursday, October 1st. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Sagimet Biosciences in a research note on Monday, October 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Sagimet Biosciences in a report on Thursday, October 1st. Finally, The Goldman Sachs Group initiated coverage on shares of Sagimet Biosciences in a research report on Thursday, September 24th. They issued a “sell” rating and a $7.00 price objective on the stock. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body’s production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.